Kevin Sheth, MD

Dr. Kevin Sheth is a founding Director of the Yale Center for Brain & Mind Health and the founding Chief of the Division of Neurocritical Care & Emergency Neurology. He leads prevention efforts in neurologically vulnerable populations and works towards advancing therapies for acute brain injury such as stroke and brain hemorrhage. In pioneering the development of new strategies to treat brain swelling, his work has changed the fundamental approach to brain injury in the ICU and spurred the creation of new technologies in drug delivery and neuroimaging. Highly collaborative, interdisciplinary efforts from the lab have culminated in the first phase III trial to prevent brain swelling in stroke, the first phase III NIH funded prevention trial in brain hemorrhage, and the deployment of the first portable bedside MRI for brain injury in the world. His team at Yale has served as a national model for academic critical care neurology units.

He is currently a principal investigator for three NIH neuroscience networks, NeuroNEXT, StrokeNet, and SIREN. He is a multi-PI for four additional RO1/UO1 awards from the NIH. Dr. Sheth has served as PI or co-PI for 8 multicenter clinical trials in stroke. He is a winner of the prestigious Robert Siekert Award from the American Heart Association (AHA), the Derek Denny Brown Award from the American Neurological Association and an elected member of the American Society for Clinical Investigation (ASCI). Most recently, he was the recipient of the Stroke Research Mentorship Award from the American Heart Association. Dr. Sheth is the author of over 300 publications. He serves on the American Neurological Association Board of Directors. His work has been showcased in The Washington Post, Wall Street Journal, Scientific American, NPR, and CNN.

Finally, Dr. Sheth has formed exciting partnerships with entrepreneurs, pharmaceutical companies, and medical device start-ups to bring forward highly innovative solutions. These efforts have resulted in extensive knowledge of FDA pathways, development of phase I-III drug programs, and implementation of new technology into the clinical workspace. The principal theme of his efforts are towards collaboration and an improved understanding of neurological disease.